{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:27:18Z","timestamp":1791235638606,"version":"4.1.0"},"reference-count":21,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T00:00:00Z","timestamp":1682121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare treatment response in women who did and did not develop a urinary tract infection (UTI) within 14 days after intravesical onabotulinumtoxinA injections for treatment of refractory urgency urinary incontinence (UUI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This is a secondary analysis of women who received Onabotulinumtoxin A in the Refractory Overactive Bladder: Sacral Neuromodulation vs Botulinum Toxin Assessment (ROSETTA) Trial. Participants were grouped by presence or absence of UTI within 14 days of injection. UTI was defined as symptomatic with positive urine culture per the primary ROSETTA protocol. Our primary outcome was change from baseline in mean number of UUI episodes based on monthly 3\u2010day bladder diaries averaged over 6 months. We performed\n                      <jats:italic>t<\/jats:italic>\n                      tests and chi\u2010square\/Fisher's exact for continuous and categorical variables. A\n                      <jats:italic>p<\/jats:italic>\n                      value of &lt;0.05 was considered statistically significant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 187 participants in the onabotulinumtoxinA arm, 10 (5.3%) experienced UTI within 14 days of injection, and 177 (94.7%) did not. At baseline, groups did not differ in demographics, mean UUI episodes per day (no UTI [5.37\u2009\u00b1\u20092.65] vs. UTI [6.40\u2009\u00b1\u20093.02],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.24), or other diary parameters. For our primary outcome, groups did not differ in the change in mean daily UUI episodes at 1 month (no UTI [\u22124.29\u2009\u00b1\u20092.75] vs. UTI [\u22123.74\u2009\u00b1\u20092.01]; mean difference [95% confidence interval, CI] \u22120.55 [\u22122.39 to 1.28],\n                      <jats:italic>p<\/jats:italic>\n                      : 0.55) or 6 months (no UTI [\u22123.63\u2009\u00b1\u20092.89] vs. UTI [\u22122.15\u2009\u00b1\u20093.18]; mean difference [95% CI] \u22121.48 [\u22123.44 to 0.48],\n                      <jats:italic>p<\/jats:italic>\n                      : 0.14).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>UTI within 14 days after intravesical injection of onabotulinumtoxinA for refractory UUI was not significantly associated with inferior treatment response at 1 or 6 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.25191","type":"journal-article","created":{"date-parts":[[2023,4,22]],"date-time":"2023-04-22T12:03:13Z","timestamp":1682164993000},"page":"1238-1244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of postinjection urinary tract infection on efficacy of intravesical onabotulinumtoxinA\u2014A secondary analysis"],"prefix":"10.1002","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6007-2688","authenticated-orcid":false,"given":"Marina","family":"Guirguis Hanna","sequence":"first","affiliation":[{"name":"Division of Urogynecology, Department of Obstetrics and Gynecology, Magee\u2010Womens Hospital of UPMC University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Bradley","sequence":"additional","affiliation":[{"name":"Division of Urogynecology, Department of Obstetrics and Gynecology, Magee\u2010Womens Hospital of UPMC University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Zyczynski","sequence":"additional","affiliation":[{"name":"Division of Urogynecology, Department of Obstetrics and Gynecology, Magee\u2010Womens Hospital of UPMC University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical and Translational Science Institute University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Giugale","sequence":"additional","affiliation":[{"name":"Division of Urogynecology, Department of Obstetrics and Gynecology, Magee\u2010Womens Hospital of UPMC University of Pittsburgh Pittsburgh Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-002-0301-4"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.12137"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.14617"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2011.09.019"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2014.01.009"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.17219\/acem\/90764"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.04.103"},{"key":"e_1_2_9_9_1","unstructured":"Allergan. BOTOX\u00ae (onabotulinumtoxinA) for Injection for Intramuscular Intradetrusor or Intradermal Use. 2022."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-016-3212-4"},{"key":"e_1_2_9_11_1","unstructured":"UpToDate. OnabotulinumtoxinA (Botox): Drug information. Lexicomp Inc. 2022. Accessed March 10 2022.https:\/\/www.uptodate.com\/contents\/onabotulinumtoxina-botox-drug-information?topicRef=13643&source=see_link"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.02.011"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.20705"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140206"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6777(2000)19:2<137::AID-NAU4>3.0.CO;2-G"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.379"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2017.10.006"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24845"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.24169"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-019-04007-7"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2022.05.003"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-020-04230-7"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25191","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T16:34:17Z","timestamp":1692203657000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.25191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,22]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1002\/nau.25191"],"URL":"https:\/\/doi.org\/10.1002\/nau.25191","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,22]]},"assertion":[{"value":"2022-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}